NSE: GLENMARK | BSE: 532296

Mid-range Performer

Download real time

2025.00 6.40 (0.32%)

58.76% Gain from 52W Low

294.5K NSE+BSE Volume

NSE 25 Sep, 2025 9:43 AM (IST)

57,145.7

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Glenmark Pharmaceuticals Ltd. is on 26 Sep 2025 for the purpose of Interim Dividend See details

Glenmark Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLENMARK, BSE:532296 Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd.

03 Jun 2015

2025.00

0.32%

Glenmark 3June2015

Buy: Glenmark Pharmaceuticals Ltd.

Phillip Capital

broadbased improvement in US sales (20%), domestic formulations (1719%), and in EuropeandROWmarkets.IttargetsanEBITDAofRs17.5bn,implyingamarginof~22% (lower than our estimate of 22.7%) and tax incidence of 2324% (we factored 22%). The...

Glenmark Pharmaceuticals Ltd. has gained 35.66% in the last 6 Months

Is Glenmark Pharmaceuticals Ltd. worth buying?

571 Votes:

Buy 79.33%

Sell 13.66%

Hold 7.01%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf